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SLEAbstract Objective: To elucidate early coronary atherosclerotic changes in premenopausal sys-
temic lupus erythematosus (SLE) female patients without clinical cardiovascular manifestation
using a 64-slice Multi-detector computed tomography (MDCT) scan to detect coronary calciﬁca-
tion and measure coronary calcium score (CCS), and to ﬁnd out its correlation to some traditional
and non-traditional risk factors.
Methodology: Sixty consecutive premenopausal SLE female patients, and sixty age and sex
matched healthy subjects without known systemic, immunological, or cardiovascular disease
(served as a control group) underwent clinical examination, serological analysis, and 64-slice
MDCT-based coronary calcium scoring. All the clinical, serological, and MDCT parameters of
the patients were correlated.
Results: Coronary calciﬁcation (CC) was seen in 21 patients (35%), the number of atherosclerotic
calciﬁed plaques ranged from 0 to 19. Calcium scores ranged from 0 to 843. In contrast to control
subjects, SLE patients had signiﬁcantly higher erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), total cholesterol level, low-density lipoprotein (LDL), immunoglobulin G (IgG)
and IgM anti-cardiolipin antibodies, serum intracellular adhesion molecule (sICAM) and E-selectin
levels. SLE patients had highly signiﬁcantly more atherosclerotic plaques (3 ± 0.66 compared to
0.1 ± 0.07, p< 0.001) and higher CCS (59.2 ± 20.3 compared to 2.6 ± 1.85, p< 0.001). Signiﬁ-
cant positive correlation was found between both number of atherosclerotic plaques and CCS
282 K.M.S. Othman, N.Y. Assafand total cholesterol level, LDL, cumulative prednisone dose, SLE disease activity index (SLE-
DAI), ESR, CRP, sICAM-1, E-Selectin, and anti-cardiolipin antibodies (p< 0.05 in all).
Conclusion: Pre-menopausal SLE female patients free from clinical atherosclerotic vascular disease
have an increased number of atherosclerotic plaques and CCS, which correlate positively with SLE-
DAI disease activity score, serum CRP, anticardiolipin antibodies, sICAM-1, E-Selectin, LDL
level, total cholesterol level, and cumulative prednisone dose. In addition, we conclude that MDCT
is a non-invasive, sensitive, reproducible, and reliable tool for accurate measurement of coronary
calciﬁcation.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Systemic lupus erythematosus (SLE) is a systemic inﬂamma-
tory disease that affects primarily women and causes chronic
vascular inﬂammation.1 Women with SLE have a high fre-
quency of coronary artery disease (CAD) and exhibit high
rates of myocardial infarction that are up to 52 times higher
than in women without SLE in the age between 35 and
44 years.2 As treatments for lupus itself have generally im-
proved, direct mortality rates have declined and cardiovascular
co-morbidities have become a growing clinical problem. Circu-
latory diseases are today a leading cause of mortality among
SLE patients.3 Several studies of subclinical atherosclerosis
have identiﬁed that 30–40% of women with SLE have myocar-
dial perfusion abnormalities.4–6
There has been a growing interest in the hypothesis that
atherosclerosis may be an immune-inﬂammatory disease; in
this regard, SLE is an interesting model because it represents
an inﬂammatory disease of autoimmune origin.7
The mechanism of accelerated atherosclerosis in SLE is
not clear. Several factors have been implicated for the high
prevalence of premature CAD; these factors are a mixture be-
tween traditional risk factors and factors associated with the
disease itself or its treatment. SLE patients have increased
prevalence of conventional risk factors like hypercholesterol-
emia, diabetes mellitus, obesity, hypertension, and sedentary
life.8 Risk factors related to SLE and its treatment include
the presence of anti-phospholipid antibodies like anti-cardio-
lipin antibodies (aCL), which are considered as an indepen-
dent risk factor for myocardial infarction,9 corticosteroid
therapy either due to their direct atherogenic effects or
through enhancement of traditional risk factors such as
hyperlipidemia, hyperglycemia, hypertension, and obes-
ity.10,11 Also having SLE is considered an independent risk
factor for cardiovascular disease2; the ongoing inﬂammatory
process accompanying multiple immunological and procoagu-
lant abnormalities in SLE12, and the underlying genetic sus-
ceptibility to develop accelerated atherosclerosis in patients
with SLE may play a role.13
Coronary calcium is closely associated with the presence
and extent of atherosclerotic plaque and therefore constitutes
a potential marker for early stages of coronary atherosclerosis
in asymptomatic subjects.14
Therefore, this study was planned to elucidate early coro-
nary atherosclerotic changes in premenopausal SLE female pa-
tients without clinical cardiovascular manifestation, using a
64-slice MDCT scan to detect coronary calciﬁcation and mea-
sure coronary calcium score, and to ﬁnd out its correlation to
some traditional and non-traditional risk factors.2. Patients and methods
Between June 2010 and April 2012, sixty consecutive premeno-
pausal SLE female patients fulﬁlling the criteria of the Amer-
ican College of Rheumatology (ACR) for the classiﬁcation of
SLE15 were studied. We included only premenopausal women
in order to avoid the strong confounding effect of low estrogen
levels on the risk of vascular disease. We excluded patients
with juvenile onset SLE; patients with other connective tissue
diseases; clinical atherosclerotic vascular disease (previous car-
diac, cerebral, or peripheral vascular affection); family history
of premature CAD; diabetes mellitus; arterial hypertension;
current smoking habit; or birth control using oral contracep-
tive pills so that we can limit the causes of early atherosclerotic
changes in premenopausal female patients to the effect of SLE
and/or its therapy. A group of sixty healthy female subjects of
matched age (age is a known strong predictor of atherosclero-
sis) without known systemic, immunological, or atheroscle-
rotic vascular disease served as a control group. The Royal
Commission Hospital Ethics and Research Committee ap-
proved the study on March 2010.
At the time of the study, detailed disease and medication
history (steroid intake duration, dosage, and frequency); calcu-
lation of body mass index (BMI) according to the following
equation: BMI = Body weight in kg/Height in m.2 assessment
of disease activity using the SLE Disease Activity Index (SLE-
DAI) according to Bombardier et al. (1992)16; laboratory
assessment of complete blood count (CBC) using Coulter
Counter T660, erythrocyte sedimentation rate (ESR) using
the Westergren method, C-reactive protein (CRP) using the
ELISA technique, antinuclear antibodies (ANA) by indirect
immune-ﬂorescence using Kallestad kit, anti-double stranded
DNA by the indirect immune-ﬂuorescence technique, anti-car-
diolipin antibodies (IgG and IgM) by enzyme linked immuno-
sorbent assay (ELISA) according to Harris et al. (1987),17 and
12 h fasting lipid proﬁle (including total cholesterol, triglycer-
ides, LDL-cholesterol, and HDL-cholesterol) using CX5 sys-
tem (Beckman US) were performed.
2.1. Coronary calcium scoring protocol
Patients were scanned using a 64-slice CT scanner (General
Electrics LightSpeed VCT, Milwaukee, WI, USA). A non-en-
hanced low-dose ECG-gated scan covering the whole heart
during a single breath hold was performed at 70–75% of the
R–R interval using the following scan parameters: detector
coverage 1.25 mm; gantry rotation time 350 ms; tube voltage
120 kV; and tube current 180–200 mA. Datasets were recon-
structed from the retrospectively gated raw data. Images were
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onary arteries were evaluated using the reconstruction dataset
with the least motion artifacts, typically an end-diastolic phase.
The effective dose of the CS scans was estimated from the
dose-length product and an organ weighting factor
[k= 0.014 mSv X (mGy X cm)1] for the chest as the investi-
gated anatomical region.18 For data analysis post-processing
of the CS examinations was performed on dedicated worksta-
tions (Vitrea2, Vital Images, USA and Advantage, GE Health-
care, USA). The CS was calculated using the Agatston
method.19 All scans were interpreted by the same cardiologist
who was unaware of the subjects’ clinical status at the time of
interpretation. Coronary calcium was assumed to be present if
a computed tomography attenuation value of at least 130
Hounsﬁeld units (HU) was found in two or more adjacent pix-
els which could be assigned to the coronary artery system.
Semi automated software was used to calculate the ‘‘Agatston
score’’ after manual identiﬁcation of calciﬁed lesions in the
coronary arteries. Coronary artery calcium (CAC) score was
categorized based on the published guidelines that corre-
sponded to the probability of signiﬁcant CHD: 0 (very low
probability of CHD), 1–10 (very unlikely CHD), 11–100 (likely
mild to minimal coronary stenosis), >100–400 (non-obstruc-
tive CHD), and >400 (high likelihood of >1 ‘‘signiﬁcant’’
coronary stenosis) with a very high risk for future events due
to coronary artery disease.20
2.2. Statistical analysis
Data were collected, tabulated, and analyzed using the scien-
tiﬁc package of social statistics program. The mean and stan-
dard deviation were determined and the statistical
signiﬁcance was calculated using Student’s ‘‘t’’ test for paired
data. The Mann–Whitney (U) test using standard error of
the mean to calculate z was used for comparison of the coro-Table 1 Comparison between patients and control regarding demo








Total cholesterol 212.90 43.60
LDL cholesterol 139.80 23.20
HDL cholesterol 46.74 18.40
Triglycerides 118.19 30.10
IgG aCL (GPL units/ml) 25.90 12.60
IgM aCL (MPL units/ml) 13.15 3.76
sICAM 289.20 66.20
E-Selectin 72.30 9.60
Number of atherosclerotic plaques 3 0.66*
CCS 59.2 20.3*
BMI = body mass index, SSBP = sitting systolic blood pressure, SDBP
rate, CRP= C-reactive protein, LDL= low density lipoprotein, HD
sICAM-1 = soluble intercellular adhesion molecule-1, MDCT=Multi d
* Standard error of the mean.
** z Value.nary calciﬁcation parameters. The Chi square test was used
to compare the probability of having CHD based on coronary
calcium score categorization. A value of p< 0.05 was consid-
ered statistically signiﬁcant. Correlation coefﬁcient ‘‘r’’ for the
relationship of different variables was calculated using Pear-
son’s coefﬁcient for quantitative data and spearman correla-
tion for qualitative (non-parametric) data.
3. Results
This cross sectional observational study was carried out on 60
consecutive premenopausal SLE female patients and 60 con-
trols during the period from 06/2010 to 4/2012.
3.1. Demographic and clinical characteristics of control group
A group of 60 healthy female subjects, ranged in age from 18
to 41 years with a mean of 31.7 ± 5.9 years served as a control
group. None of them was known to have previous or current
systemic, immunological, or atherosclerotic vascular disease.
Demographic data, clinical, laboratory, number of atheroscle-
rotic plaques and CCS of controls are summarized in Table 1.
Coronary calciﬁcation (CC) was seen in two subjects
(3.3%) of the control group, the number of atherosclerotic cal-
ciﬁed plaques ranged from 0 to 3 (mean 0.1 ± 0.07), Calcium
scores ranged from 0 to 83 (mean 2.6 ± 1.85) (Table 2).
3.2. Demographic and clinical characteristics of patients
This study included sixty consecutive premenopausal SLE pa-
tients ranged in age from 18 to 40 years with a mean of
31.4 ± 6 years. All of them were diagnosed as having SLE
based on the criteria of the American College of Rheumatol-
ogy for the classiﬁcation of SLE.13 The disease duration ran-graphic data, clinical, laboratory, and MDCT results.
Controls (No = 60) T-test
Mean SD t p-Value
31.70 5.90 0.28 (p> 0.05) NS
25.70 3.90 0.37 (p> 0.05) NS
119.00 18.00 0.76 (p> 0.05) NS
80.00 6.00 0.84 (p> 0.05) NS
12.10 5.00 16.48 (p< 0.001) HS
5.00 2.00 26.35 (p< 0.001) HS
179.20 23.40 5.27 (p< 0.05) S
102.30 21.20 9.24 (p< 0.05) S
56.34 14.10 3.21 (p< 0.05) S
113.17 21.40 1.05 (p> 0.05) NS
10.84 5.80 21.76 (p< 0.001) HS
4.14 2.90 25.45 (p< 0.001) HS
201.10 19.40 9.89 (p< 0.05) S
43.20 2.20 8.92 (p< 0.05) S
0.1 0.07* 4.46** (p< 0.001) HS
2.6 1.85* 4.38** (p< 0.001) HS
= sitting diastolic blood pressure, ESR= erythrocyte sedimentation
L = high density lipoprotein, aCL= Anti-cardiolipin antibodies,
etector CT, CCS = coronary calcium score.
Table 2 Distribution of coronary calciﬁcation in SLE patients
and controls.
Coronary arteries Patients: No. (%) Control: No. (%)
LAD 8 (38.1%) 1 (50%)
Lt CX 2 (9.5%) 0
RCA 4 (19.0%) 0
LAD+ Lt CX 1(4.8%) 0
LAD+RCA 3(14.3%) 1 (50%)
Lt CX+ RCA 0 0
LAD+ Lt CX+ RCA 3 (14.3%) 0
Total 21 (100%) 2 (100%)
LAD= left anterior descending artery, Lt CX= left circumﬂex,
RCA= right coronary artery.
Figure 1 Example of MDCT in SLE patient, one calciﬁed
plaque is seen in the left anterior descending artery (blue color)
and two calciﬁed plaques in the circumﬂex artery (yellow color).
Figure 2 Example of MDCT in SLE patient, one calciﬁed
plaque is seen in the right coronary artery (red color).
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them had no clinical atherosclerotic vascular manifestations on
examination. Demographic data, clinical, laboratory, number
of atherosclerotic plaques and CCS of patients are summarized
in Table 1.
Coronary calciﬁcation (CC) was seen in 21 patients (35%),
the number of atherosclerotic calciﬁed plaques ranged from 0
to 19 (mean 3 ± 0.66), calcium scores ranged from 0 to 843
(mean 59.2 ± 20.3) (Table 2).
Sub-group analysis for the distribution of coronary calciﬁ-
cation according to the coronary artery/s affected in both SLE
patients and control subjects is shown in Table 2, Figs. 1 and 2.
Further categorization of CAC score in both SLE patients and
controls based on the probability of signiﬁcant coronary heart
disease (CHD) is shown in Table 3.
At the time of the study, all patients received prednisone
regularly, with a mean dose of 25 mg/day and a cumulative
dose of 32 ± 11.6 g.
SLE patients had signiﬁcantly higher ESR, CRP, total cho-
lesterol, and LDL levels; signiﬁcantly lower HDL levels; and
signiﬁcantly higher IgG aCL, IgM aCL, sICAM, and E-Selec-tin levels. SLE patients had highly signiﬁcantly more athero-
sclerotic plaques and higher CCS. On the other hand, no
statistically signiﬁcant differences were detected between pa-
tients and control regarding the age, BMI, systolic and dia-
stolic blood pressure, or triglyceride levels (Table 1).
The probability of having CAD was signiﬁcantly higher in
SLE patients in comparison to control as only 65% of the SLE
patients had zero CCS (very low probability of CHD) in com-
parison to 96.7% of the control p< 0.000. Twenty percentage
of the SLE patients had CCS from 11–100 (likely mild to min-
imal coronary stenosis) in comparison to only 3.3% of the con-
trol subjects p< 0.001. Moreover the probability of having
signiﬁcant CAD was higher in SLE patients in comparison
to control, 10% of the SLE patients had CCS of >100–400
(non-obstructive CHD) and 5% of the SLE patients had
CCS of > 400 (high likelihood of signiﬁcant coronary steno-
sis) while no subjects in the control group had CCS >100 with
a highly signiﬁcant p value < 0.001 in both (Table 3).
On studying the correlation between the various data of the
SLE patients, using Pearson’s correlation coefﬁcient we found
signiﬁcant positive correlation between both number of ath-
erosclerotic plaques and CCS and total cholesterol level,
LDL level, cumulative prednisone dose, SLEDAI disease
activity score, ESR, CRP, sICAM-1, E-Selectin, and anti-car-
diolipin antibodies (p< 0.05 in all). Signiﬁcant negative corre-
lation was also found between number of atherosclerotic
plaques and CCS and HDL. On the other hand no signiﬁcant
ﬁxed correlation was found between number of atherosclerotic
plaques and CCS and any of patients’ age, disease duration,
body mass index, SSBP, SDBP, and serum triglyceride level
(Table 4).
4. Discussion
There has been a growing interest in the hypothesis that ath-
erosclerosis may be an immune-inﬂammatory disease; in this
regard, SLE is an interesting model of atherosclerosis because
it represents an inﬂammatory disease of autoimmune origin.7
Compared with women in the general population, women with
Table 3 Coronary calcium score categorization in SLE patients and controls.
Coronary calcium score Patients: No. (%) Control: No. (%)
0 (very low probability of CHD) 39 (65%) 58 (96.7%)
1–10 (very unlikely CHD) 3 (5%) 0
11–100 (likely mild to minimal coronary stenosis) 12 (20%) 2 (3.3%)
>100–400 (non-obstructive CHD) 4 (10%) 0
>400(high likelihood of ‘‘signiﬁcant’’ coronary stenosis) 2 (5%) 0
Total 60 (100%) 60 (100%)
Table 4 Correlation between number of atherosclerotic plaques and CCS and demographic, clinical, and laboratory results in SLE
patients.
Parameter Number of atherosclerotic plaques CCS
r p r p
Age (years) 0.19 .066 0.20 .060
Disease duration (years) 0.10 .080 0.21 .065
BMI (kg/m2) 0.12 .075 0.08 .570
SSBP (mm Hg) 0.06 .650 0.22 .061
SDBP (mm Hg) 0.09 .075 0.07 .600
ESR (mm/1st hour) 0.26 .045 0.28 .040
CRP (mg/l) 0.35 .010 0.33 .020
Total cholesterol (mg/dl) 0.39 .008 0.43 .003
LDL cholesterol (mg/dl) 0.46 .001 0.51 .000
HDL cholesterol (mg/dl) 0.42 .003 0.59 .000
Triglycerides (mg/dl) 0.06 .700 0.03 .785
IgG aCL 0.29 .038 0.25 .050
IgM aCL 0.24 .048 0.27 .043
sICAM (ng/ml) 0.26 .041 0.28 .040
E-Selectin (ng/ml) 0.25 .038 0.31 .022
SLEDAI 0.29 .035 0.37 .009
Cumulative prednisone level (gm) 0.31 .022 0.38 .008
BMI = body mass index, SSBP = sitting systolic blood pressure, SDBP= sitting diastolic blood pressure, ESR= erythrocyte sedimentation
rate, CRP= C-reactive protein, LDL= low-density lipoprotein, HDL= high-density lipoprotein, aCL= Anti-cardiolipin antibodies,
sICAM-1 = soluble intercellular adhesion molecule-1, SLEDAI = systemic lupus disease activity index, CCS = coronary calcium score.
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this risk being particularly marked in women younger than age
55 years.21 The risk of a CVE, or MI, was eight- or ninefold
greater among middle-aged female SLE patients.22 Doyle
et al., 2009, reported a case of acute myocardial infarction
due to coronary artery thrombosis as the presenting manifesta-
tion of SLE in a 12 year old female child.23
Coronary calcium deposits provide an independent predic-
tion of short and long-term cardiac events. Even in patients
with normal SPECT results, the increased coronary calcium
score identiﬁes subjects at high long-term cardiac risk.24
MDCT is characterized by very high speciﬁcity (95–97%)
and excellent negative predictive value (93–99%) for stable
coronary artery disease diagnosis.25 Coronary calciﬁcation de-
tected by MDCT independently predicts CVS events in pa-
tients with RA and SLE. Risk stratiﬁcation by assessment of
CCS may have an important role in patients with systemic
inﬂammatory disease.26 Thus; an early stage of coronary artery
disease may be diagnosed in patients with atherosclerotic pla-
ques detected by MDCT.
This study was designed to elucidate early preclinical ath-
erosclerotic changes in premenopausal SLE female patients
using a 64-slice MDCT scan to detect coronary calciﬁcationand measure coronary calcium score as a non-invasive, sensi-
tive, and reproducible screening tool for the detection of sub-
clinical coronary affection in SLE patients, and to study their
correlation to some traditional and non traditional CAD risk
factors for possible implementation of preventive measures
and initiation of therapy early in the course of the disease.
Our results showed that coronary atherosclerotic lesions
(CC) were seen in 21 premenopausal SLE patients without
clinically overt atherosclerotic vascular disease (35%), highly
signiﬁcant differences between patients and control regarding
the number of atherosclerotic plaques and CCS (p< 0.001
in both) were also detected.
These ﬁndings reﬂecting higher incidence of subclinical ath-
erosclerosis in premenopausal SLE female patients can be ex-
plained by the contribution of SLE with its systemic nature to
atherosclerosis by more than one mechanism. Early immune
system dys-regulation and altered complement metabolism
may reduce arterial elasticity, creating an atherogenic milieu;
changes in the geometric conﬁguration of vessels may lead to
smooth muscle cell proliferation and increased collagen depo-
sition; the intimal layer of these stiffened vessels then becomes
vulnerable to atherosclerosis with increased lipoprotein, albu-
min, and leukocyte permeability. Thus, an early effect of
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tion of the atherosclerotic process through traditional risk fac-
tors.27 In addition, the inﬂammatory process associated with
SLE may affect the vessel wall thickness and the development
of plaque. It is now generally believed that inﬂammation plays
an integral role in atherogenesis, and that prolonged exposure
to even low levels of acute-phase reactants may cause vascular
injury leading to cardiovascular disease.28
Our results are in agreement with earlier studies done by
Kao et al., 2008, in the ﬁrst study to compare the prevalence
of coronary artery calciﬁcation among non-diabetic and age-
matched female patients with SLE, RA, and healthy controls
who found that in young subjects with the mean age of 40,
the frequency of coronary artery calciﬁcations is 30–40%.29
In addition, in a study done by Yiu and his colleagues in
2009, who studied 50 SLE patients and found that the fre-
quency of atherosclerotic plaques observed in MDCT was
highest in coronary arteries (42%) of patients with calciﬁca-
tions.30 Recent studies showed that 25% of asymptomatic
SLE patients manifested with atherosclerosis in coronary
arteries31 and CAC was present in 17% of SLE patients.32
On studying the correlation between the various data of the
SLE patients, we found signiﬁcant positive correlation between
both number of atherosclerotic plaques and CCS and total
cholesterol level, LDL level, cumulative prednisone dose, SLE-
DAI disease activity score, ESR, CRP, sICAM-1, E-Selectin,
and anti-cardiolipin antibodies (p< 0.05 in all). Signiﬁcant
negative correlation was also found between number of ath-
erosclerotic plaques and CCS and HDL. On the other hand
no signiﬁcant ﬁxed correlation was found between number of
atherosclerotic plaques and CCS and any of patients’ age, dis-
ease duration, body mass index, SSBP, SDBP, and serum tri-
glyceride level.
Increased risk of coronary artery calciﬁcation in SLE pa-
tients with higher levels of CRP can be explained by the
inﬂammatory microenvironment in SLE that promotes the for-
mation of oxidized LDL which is responsible for the oxidative
injury of vascular wall.33 CRP induces the expression of adhe-
sion molecules on the endothelial surface (including vascular
cell adhesion molecule-I, intercellular adhesion molecule-I,
and E-selectin) and promotes the adherence of leucocytes with
the resultant initiation of vascular atherosclerotic damage.34
CRP in particular has been emerging as a strong predictor of
CAD outcomes.35 Prolonged exposure to even low levels of
acute-phase reactants may cause vascular injury leading to car-
diovascular disease.1
Our results are in agreement with Kao et al., 2008, who
showed that coronary artery calciﬁcation in female patients
with SLE may be linked to CRP and he reported that this
is consistent with the exceedingly high risk of myocardial
infarction in young women with SLE independent of tradi-
tional CHD risk factors. Their study also supports the notion
that inﬂammation and endothelial activation may play the
most signiﬁcant roles in accounting for this excess risk.29
Pons-Estel et al., 2009, showed that SLE patients with CRP
levels > 20 mg/l were at increased risk of cardiovascular
damage.36
On the other hand, the study of Plazak and his colleagues in
2011, did not show an inﬂuence of hyperlipidemia on coronary
calciﬁcation formation or myocardial perfusion defects in SLE
patients. Moreover, they reported that a generalized inﬂamma-
tion reﬂected by higher CRP did not signiﬁcantly resulted inthe presence of atherosclerotic lesions. They explained their re-
sults by the lack of subjects with severely augmented inﬂam-
matory process in their study.31
The conventional risk factors for coronary artery disease
(increased total cholesterol and LDL) in our study, cannot
alone explain the increased risk of atherosclerosis and cardio-
vascular complications in SLE patients. The other possible
mechanisms include a generalized, chronic inﬂammation, re-
ﬂected by high C-reactive protein level.36 Besides the chronic
inﬂammation, the second factor that may potentially inﬂuence
pathologic changes in the arteries is the presence of anti-
phospholipid antibodies.37
Among the possible known mechanisms for the role of anti-
phospholipid antibody mediated vascular injury is the
enhancement of the expression of ICAM-1, VCAM-1, and
E-selectin on endothelial cells (ECs) and that these effects
are correlated with increased adhesion of leukocytes to endo-
thelium. Activation of ECs by antiphospholipid antibody
(aPL) may create a hypercoagulable state that precedes and
contributes to thrombosis in SLE patients.37 In addition, Lima
et al., 2002, reported that it is possible that in the subgroup of
SLE patients with positive aPL, the smooth muscle cell prolif-
eration takes place earlier than in the SLE group without
aPL.10 It is of interest to note that antibodies against cardio-
lipin were predictive of MI in SLE patients approximately
one decade earlier than antibodies against ox LDL. Thus, indi-
viduals with antibodies against cardiolipin seem to have a
more unfavorable outcome of the disease.38 Vaarala et al.,
1995, in a prospective cohort of healthy middle-aged men con-
cluded that, aCL level is considered an independent risk factor
for myocardial infarction.9 In SLE patients, CAD has been
correlated with aCL and anti-oxidized LDL antibodies.39
These ﬁndings along with increased lipid peroxidation in
aCL positive SLE patients suggest that the presence of these
antibodies can be associated with subclinical atherosclerosis
in SLE patients.40
Our results are in agreement with Rho et al., 2009, who
concluded that the adhesion molecules VCAM, ICAM, and
E-selectin, and the cytokine TNF-a are associated with coro-
nary atherosclerosis independent of the conventional risk fac-
tors.41 They studied a population with asymptomatic,
subclinical atherosclerosis, and their ﬁndings suggest that
adhesion molecules and TNF-a may contribute at a relatively
early stage of atherosclerotic vascular disease in this popula-
tion and therefore may represent a potential target for the pre-
vention of subsequent symptomatic atherosclerosis in patients
with SLE.
Gustafsson et al., 2009, in their prospective study to inves-
tigate lupus associated CAD risk factors for the ﬁrst ever car-
diovascular event (CVE) in patients with SLE reported that
positive aPL, and biomarkers indicating increased endothelial
cell activity are independent predictors of CVEs.3 Their results
indicate that activation of the endothelium and the coagula-
tion system are important features in SLE related CVD. Fur-
thermore, they observed that the risk of CVEs seems to
increase in SLE patients with positive aPL, elevated von Wille-
brand factor (vWf), and soluble VCAM1.3
Plazak et al., 2011, showed an association of coronary cal-
ciﬁcation formation in SLE patients with the presence of anti-
phospholipid antibodies.31 Various studies have suggested that
antiphospholipid antibodies may cause thrombosis by activa-
tion of endothelial cells or platelets or by inhibition of the pro-
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may also initiate or exacerbate the process of lipid deposition
and plaque formation.42
Assessment of disease activity score at the time of the scan
cannot accurately reﬂect the level of lupus activity throughout
the course of the disease. Average activity scores over a longer
period may provide more accurate estimates of lupus activity
and its relationship to atherosclerosis.2
Our study showed a signiﬁcant positive correlation between
both number of atherosclerotic plaques and CCS and the
cumulative prednisone dose. This could be explained by direct
atherogenic effects of steroids or through enhancement of tra-
ditional factors such as hyperlipidemia, hyperglycemia, hyper-
tension, and obesity.10 Alekberova et al., 2004, found an
association between duration of use and cumulative doses of
corticosteroid and plaque formation.11,43 Doria et al., 2003,
showed that in SLE patients the most important non-tradi-
tional risk factor for atherosclerosis was the cumulative corti-
costeroid dose.7 Steroid treatment is often believed to be
atherogenic due to the effect on plasma lipoproteins, but
inﬂammation is implicated in atherosclerosis, so steroids could
possibly prevent atherosclerosis as well. Clearly, the role of ste-
roid treatment in development of arterial disease in SLE de-
serves further study.11,44
4.1. Study limitations
This study has an important limitation which is the cross sec-
tional nature that may fail to estimate the true magnitude for
the contribution of variables such as disease activity and ther-
apy. A prospective study might demonstrate a greater effect
over time.
5. Conclusion
This study demonstrated that pre-menopausal SLE female pa-
tients free from clinical atherosclerotic vascular disease have
an increased number of atherosclerotic plaques and CCS,
which correlates positively with SLEDAI disease activity
score, serum CRP values, anticardiolipin antibody, sICAM-
1, E-Selectin, LDL level, total cholesterol concentration, and
cumulative prednisone dose. In addition, we conclude that
MDCT is a non-invasive, sensitive, reproducible, and reliable
tool for accurate measurement of coronary calciﬁcation, that
indirectly reﬂects subclinical coronary affection, and it is con-
sidered a useful tool for the follow up of the course of athero-
sclerosis over time.
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